Facing multi-drug resistant tuberculosis

Pulmonary Pharmacology and Therapeutics

Volumn 32, Issue , 2015, Pages 144-148

  Sotgiu, Giovanni ^a   Migliori, Giovanni Battista ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b IRCCS   (Italy)

Author keywords

Elimination; MDR TB; Mycobacterium tuberculosis; Second line drugs; Stop TB strategy; XDR TB

Indexed keywords

BEDAQUILINE; CLAVULANIC ACID; LINEZOLID; MEROPENEM; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; ASIA; CONSULTATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; EASTERN EUROPEAN; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FOLLOW UP; HUMAN; INCIDENCE; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RISK FACTOR; SHORT COURSE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; DIRECTLY OBSERVED THERAPY; DRUG DESIGN; DRUG EFFECTS; ISOLATION AND PURIFICATION; MEDICATION COMPLIANCE; MICROBIOLOGY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; DRUG DESIGN; HUMANS; ISONIAZID; MEDICATION ADHERENCE; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84930510601     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.04.006     Document Type: Article

References (40)

1. Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 2003, 16(3):463-496.
2. Huynh K.K., Joshi S.A., Brown E.J. Adelicate dance: host response to mycobacteria. Curr Opin Immunol 2011, 23(4):464-472.
3. Dheda K., Migliori G.B. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?. Lancet 2012, 379(9817):773-775.
4. Rieder H. Epidemiologic basis of tuberculosis control 1999, International Union Against Tuberculosis and Lung Disease, Paris.
5. Lienhardt C., Glaziou P., Uplekar M., Lönnroth K., Getahun H., Raviglione M. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol 2012, 10:407-416.
6. Migliori G.B., Sotgiu G., Lange C., Centis R. Extensively drug-resistant tuberculosis: back to the future. Eur Respir J 2010, 36(3):475-477.
7. World Health Organization Global tuberculosis report 2013 2013, WHO/HTM/TB/2013.11, WHO, Geneva.
8. Migliori G.B., Loddenkemper R., Blasi F., Raviglione M.C. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic?. Eur Respir J 2007, 29(3):423-427.
9. Raviglione M., Marais B., Floyd K., Lönnroth K., Getahun H., Migliori G.B., et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012, 379:1902-1913.
10. United Nations Millennium development goals report June 2011, Available:. http://www.refworld.org/cgi-bin/texis/vtx/rwmain?docid=4e42118b2.
11. WHO Global Tuberculosis Programme TB: WHO report on the tuberculosis epidemic 1997, WHO, Geneva.
12. WHO Global Tuberculosis Programme An expanded DOTS framework for effective tuberculosis control: stop TB communicable diseases 2002, WHO, Geneva.
13. WHO, Stop TB Department Progress report on the global plan to stop tuberculosis 2004, WHO, Geneva.
14. Raviglione M.C. The global plan to stop TB, 2006-2015. Int J Tuberc Lung Dis 2006, 10(3):238-239.
15. Raviglione M.C., Uplekar M.W. WHO's new stop TB strategy. Lancet 2006, 367(9514):952-955.
16. Raviglione M.C., Ditiu L. Setting new targets in the fight against tuberculosis. Nat Med 2013, 19(3):263.
17. Broekmans J.F., Migliori G.B., Rieder H.L., Lees J., Ruutu P., Loddenkemper R., et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) working group. Eur Respir J 2002, 19(4):765-775.
18. Migliori G.B., Besozzi G., Girardi E., Kliiman K., Lange C., Toungoussova O.S., et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007, 30(4):623-626.
19. Sotgiu G., Ferrara G., Matteelli A., Richardson M.D., Centis R., Ruesch-Gerdes S., et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009, 33(4):871-881.
20. Powers J.H. Antimicrobial drug development - the past, the present, and the future. Clin Microbiol Infect 2004, 10(Suppl.4):23-31.
21. Ahuja S.D., Ashkin D., Avendano M., Banerjee R., Bauer M., Bayona J.N., et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012, 9(8):e1001300.
22. Caminero J.A. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010, 14(4):382-390.
23. Diel R., Vandeputte J., de Vries G., Stillo J., Wanlin M., Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014, 43(2):554-565.
24. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008 2008, WHO, Geneva, WHO/HTM/TB/2008.402.
25. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update 2011, WHO, Geneva, WHO/HTM/TB/2011.6.
26. Falzon D., Jaramillo E., Schünemann H.J., Arentz M., Bauer M., Bayona J., et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38(3):516-528.
27. Migliori G.B., Zellweger J.P., Abubakar I., Ibraim E., Caminero J.A., De Vries G., et al. European union standards for tuberculosis care. Eur Respir J 2012, 39(4):807-819.
28. Migliori G.B., Sotgiu G., D'Ambrosio L., Centis R., Lange C., Bothamley G., et al. TB and MDR/XDR-TB in European Union and European economic area countries: managed or mismanaged?. Eur Respir J 2012, 39(3):619-625.
29. D'Ambrosio L., Tadolini M., Dupasquier S., Tiberi S., Centis R., Dara M., et al. ERS/WHO tuberculosis consilium: reporting of the initial 10 cases. Eur Respir J 2014, 43(1):286-289.
30. Falzon D., Gandhi N., Migliori G.B., Sotgiu G., Cox H.S., Holtz T.H., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013, 42(1):156-168.
31. Migliori G.B., Sotgiu G., Gandhi N.R., Falzon D., DeRiemer K., Centis R., et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013, 42(1):169-179.
32. Alsaad N., van Altena R., Pranger A.D., van Soolingen D., de Lange W.C., van der Werf T.S., et al. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur Respir J 2013, 42:504-512.
33. Sotgiu G., Centis R., D'Ambrosio L., Alffenaar J.W., Anger H.A., Caminero J.A., et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012, 40:1430-1442.
34. De Lorenzo S., Alffenaar J.W., Sotgiu G., Centis R., D'Ambrosio L., Tiberi S., et al. Efficacy and safety of meropenem-clavunate added to linezolid containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013, 41:1386-1392.
35. Srivastava S., Peloquin C.A., Sotgiu G., Migliori G.B. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?. Eur Respir J 2013, 42(6):1449-1453.
36. Diacon A.H., Pym A., Grobusch M., Patientia R., Rustomjee R., Page-Shipp L., et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. NEngl J Med 2009, 360:2397-2405.
37. Diacon A.H., Donald P.R., Pym A., Grobusch M., Patientia R.F., Mahanyele R., et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012, 56:3271-3276.
38. Gler M.T., Skripconoka V., Sanchez-Garavito E., Xiao H., Cabrera-Rivero J.L., Vargas-Vasquez D.E., et al. Delamanid for multidrug-resistant pulmonary tuberculosis. NEngl J Med 2012, 366:2151-2160.
39. Skripconoka V., Danilovits M., Pehme L., Tomson T., Skenders G., Kummik T., et al. Delamanid improves outcomes and reduces mortality for multidrugresistant tuberculosis. Eur Respir J 2013, 41:1393-1400.
40. Migliori G.B., Sotgiu G. Treatment of tuberculosis: have we turned the corner?. Lancet 2012, 380:955-957.